References
- Al-Tourah AJ, Gill KK, Chhanabhai M, . Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. J Clin Oncol 2008;26:5165–5169.
- Montoto S, Davies AJ, Matthews J, . Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol 2007;25:2426–2433.
- Bastion Y, Sebban C, Berger F, . Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol 1997;15:1587–1594.
- Eide MB, Lauritzsen GF, Kvalheim G, . High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas. A Norwegian multi centre phase II study. Br J Haematol 2011;152:600–610.
- Noy A, Schöder H, Gönen M, . The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL). Ann Oncol 2009;20:508–512.
- Al-Tourah AJ, Savage KJ, Gill KK, . Addition of rituximab to CHOP chemotherapy significantly improves survival of patients with transformed lymphoma. Blood 2007;110(Suppl. 1):Abstract 790.
- Salles G, Seymour JF, Offner F, . Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011;377:42–51.
- Morschhauser F, Seymour J, Feugier P, . Impact of induction chemotherapy on response safety and outcome in the PRIMA study. Ann Oncol 2011;22(Suppl.):Abstract 22.
- Ban-Hoefen M, Kelly JL, Bernstein SH, . High-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era. Leuk Lymphoma 2012;53:827–832.
- Schouten HC, Qian W, Kvaloy S, . High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003;21:3918–3927.
- Ghesquières H, Berger F, Felman P, . Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis. J Clin Oncol 2006;24:5234–5241.
- Gisselbrecht C, Glass B, Mounier N, . Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28:4184–4190.
- Sebban C, Brice P, Delarue R, . Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. J Clin Oncol 2008;26:3614–3620.
- Villa D, Savage K, Crump M, . Autologous and allogeneic stem cell transplantation for transformed indolent non-Hodgkin lymphoma: a report of the Canadian Blood and Marrow Transplant Group. Ann Oncol 2011;22(Suppl.):Abstract 99.
- Ritchie DS. Is allogeneic stem cell transplantation for transformed follicular lymphoma anti-lymphoma stem cell therapy? Leuk Lymphoma 2008;49:1852–1853.